A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain in the study as long as the drug is helping the cancer without unbearable side effects.

Trial Details

NCT ID
NCT07174336
Phase
PHASE3
Sponsor
Eli Lilly and Company
Status
RECRUITING
Cancer Type
ER/PR Positive (Hormone Receptor Positive) Breast Cancer
Interventions
  • LY4064809
  • Placebo
  • Ribociclib
  • Palbociclib
  • Abemaciclib
  • Anastrozole
Locations (sample)
  • Anchorage, Alaska, United States|61.21806,-149.90028
  • Chandler, Arizona, United States|33.30616,-111.84125
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Tucson, Arizona, United States|32.22174,-110.92648
  • Hot Springs, Arkansas, United States|34.5037,-93.05518

Key Eligibility Criteria

  • Are willing to follow contraception requirements. Contraceptive use by participants should be consistent with local regulations regarding the metho…
  • If assigned female at birth, pre-/peri- and postmenopausal status is allowed. Those with pre- or peri-menopausal status at study entry must agree t…
  • If assigned male at birth with an estrogen receptor positive (ER+) breast cancer diagnosis, they must agree to use hormone suppression with a GnRH …
  • Have histologically or cytologically confirmed breast cancer, defined as individuals with

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find ER/PR Positive (Hormone Receptor Positive) Breast Cancer Trials on Trialify →